Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
For full access to this article login to GEN Select now.
Refined Tools Aid in Pathway Analysis
Scientists Explore Range of Options to Remove Roadblocks Along the New Product Development Highway
- As pharma looks for better ways to build its drug pipelines, researchers are improving upon existing technologies and broadening their usage. At CHI’s recent “High Content Analysis” conference, presenters discussed new and revamped tools, and showed how these advances are helping pharma companies keep their drug pipelines active and ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.